In this study, complication rates for warfarin and intravenous heparin given for secondary stroke prevention were lower than rates reported from earlier trials and observational studies. For warfarin, however, these rates were higher than those found in more recent randomized trials. Rates were higher for heparin than for aspirin and warfarin. These rates can be used to judge the applicability of complication rates derived from ongoing clinical trials.
Ann Intern Med. 1999;130(1):14-22. doi:10.7326/0003-4819-130-1-199901050-00004